IDXX

In the past six months (April - October 2026), IDEXX Laboratories, Inc. experienced several stock-impacting events. The company announced robust second-quarter 2026 results in early August, exceeding earnings per share estimates, with third-quarter results scheduled for November 2, 2026. Product expansions included the Faecal Dx Antigen Testing Platform in the UK with Taeniid Tapeworm Detection in September 2026, and the Catalyst Platform's expansion into cardiac disease with a dual-species point-of-care NT-proBNP test in August 2026. IDEXX acquired CoVetAI, a veterinary AI platform, in September 2026. A director, Lawrence D. Kingsley, sold approximately $1.2 million of IDEXX stock in September 2026. Despite a 22.02% share price decline between September 2025 and September 2026, analysts in October 2026 maintained a 'Moderate Buy' consensus rating with significant upside potential.